VANCOUVER, British Columbia & SAN DIEGO--(BUSINESS WIRE)---- $ABCL--AbCellera and Empirico Announce Strategic Multi-Target Antibody Discovery Collaboration
TORONTO--(BUSINESS WIRE)--New findings accelerated by Cyclica’s drug discovery platform suggest lung cancer drug capmatinib may improve conditions of those infected by COVID-19
TORONTO--(BUSINESS WIRE)---- $PINK.V #AI--Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced significant progress within its ATLAS AI Project, an initiative aimed at advancing Perimeter’s next-gen artificial intelligence (AI) and machine learning tools through clinical development. Per
TORONTO--(BUSINESS WIRE)--ANTIBE THERAPEUTICS TO PRESENT AT 2021 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE
LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (Crescita or the Company), a Canadian commercial dermatology company, is pleased to announce that its President and CEO, Serge Verreault will be presenting at the upcoming Bloom Burton & Co. Healthcare Investor Conference taking place virtually on April 20 and 21, 2021. Mr. Verreault will discuss recent business highlights and the Company’s growth strategy. Members of Crescita’s management team will also
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the Company will present at the upcoming 2021 Bloom Burton Healthcare Investor Conference taking place April 20-21, 2021. The Company’s presentation will be on Tuesday, April 20, 2021 at 11:30 a.m. ET. Interested parties can access a live webcast of the presentation via a link from Zymeworks’ website at http://ir.zy
TORONTO--(BUSINESS WIRE)--Cybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug Applications
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. to Present at the Bloom Burton & Co. Healthcare Investor Virtual Conference
CAMBRIDGE, Mass. & MONTREAL, Quebec--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will present at the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference on Tuesday, April 20 at 9:30 a.m. ET. A live webcast of the presen
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company at the Bloom Burton & Co. Healthcare Investor Conference. Presentation Detail
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present Virtually at Upcoming Investor Conferences
TORONTO--(BUSINESS WIRE)--Life Sciences Ontario has joined 18 other organizations across Canada to call on the federal government to work with them to create a better environment for the development and commercialization of new vaccines, medicines and health technologies in Canada. In an advertising and social media campaign launched today, life sciences industry associations, researchers and top national and regional business organizations are asking Prime Minister Justin Trudeau and his gover
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT™, and Zanidatamab Mechanisms of Action at AACR Annual Meeting
OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Corporation”) announces that a total of 3,931 common shares will be issued at the rate of $0.58 per share to satisfy the maintenance fee of $2,280 owing in respect of the debentures issued on April 9, 2019. This issuance is further to Avivagen’s previous announcement that it had opted to issue common shares to satisfy $107,560 owing to the holders of 10% secured debentures issued by Avivagen on March 28,
OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Corporation”) announces that at the Corporation’s Annual General Meeting (AGM) held today the Corporation’s shareholders voted to support all of the resolutions that came before the meeting. The resolutions included the reappointment of McGovern Hurley LLP as Avivagen’s auditor and the election of directors. The voting results in respect of the election of directors are detailed below: Nominee % Of Votes
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, will host a virtual Investor Day webcast today from 10:30 a.m. – 12:00 p.m. ET, highlighting the progress of its proprietary RP-6306 program for tumors with genetic alterations characterized by CCNE1 amplification. The C
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that its subsidiary Talem Therapeutics LLC (“Talem”) has advanced development of a candidate panel of vetted, novel, therapeutic antibodies, collectively referred to as TATX-112, against an undisclosed target, into formal lead candidate characterization. It is well documented
MONTRÉAL--(BUSINESS WIRE)--AJOVY® now offers patients greater flexibility with two dosing options available in both an autoinjector and a prefilled syringe.
MISSISSAUGA, Ontario--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the official launch of BRUKINSA® (zanubrutinib) in Canada for the treatment of adult patients with Waldenström’s macroglobulinemia (WM). BRUKINSA was authorized for sale by Health Canada in this indication on March 1, 2021, following the previous grant of priority review in September 2
VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today presented additional efficacy data from the AURA-LV and AURORA 1 pivotal trials of LUPKYNIS™ (voclosporin) in lupus nephritis (LN). The data were shared at the National Kidney Foundation (NKF) 2021 Spring Clinical Meetings by Anca D. Askanase, M.D., M.P.H., Founder and Director of Columbia University Irving Medical Center’s Lupus Center and the Dire
WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics closes $100 million Series B financing to advance pipeline of small-molecule medicines against traditionally undruggable targets
